These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 13595753)

  • 1. [Determination of complement fixing antibody in influenza].
    ALTEVOGT R
    Arch Hyg Bakteriol; 1958 Oct; 142(7):535-9. PubMed ID: 13595753
    [No Abstract]   [Full Text] [Related]  

  • 2. The stability of human complement-fixing antibodies against lymphogranuloma venereum, psittacosis, influenza A, and influenza B antigens under various conditions of storage.
    SCHMIDT N; HARDING HB; HEPLER OE
    J Lab Clin Med; 1954 Apr; 43(4):637-46. PubMed ID: 13163563
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experiences with the micro-complement fixation reaction during the influenza epidemic of 1957].
    SPROSSIG M
    Z Hyg Infektionskr; 1958; 145(3):228-34. PubMed ID: 13625799
    [No Abstract]   [Full Text] [Related]  

  • 4. [Concentration of complement-binding influenza antigen by glycerin dialysis].
    BRAND G; KEIL AW
    Zentralbl Bakteriol Orig; 1955; 162(1-2):13-7. PubMed ID: 14360539
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparative studies of several serological methods used in diagnosis of influenza].
    SARATEANU D; DRAGANESCU N
    Stud Cercet Inframicrobiol; 1957; 8(3):369-78. PubMed ID: 13529500
    [No Abstract]   [Full Text] [Related]  

  • 6. [Biological, epidemiological and preventive aspects of pandemic influenza].
    MIRRA G
    Ann Med Nav (Roma); 1957; 62(4):409-48. PubMed ID: 13470629
    [No Abstract]   [Full Text] [Related]  

  • 7. The significance of high complement-fixing antibody titres in the serological diagnosis of influenza A.
    HENEBERG D; GERBEC M
    J Hyg Epidemiol Microbiol Immunol; 1960; 4():182-90. PubMed ID: 14401023
    [No Abstract]   [Full Text] [Related]  

  • 8. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens.
    Bartel G; Wahrmann M; Exner M; Regele H; Schillinger M; Hörl WH; Böhmig GA
    Transplantation; 2007 Mar; 83(6):727-33. PubMed ID: 17414705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influenza A, B, and C complement fixing antibodies in the population of Greece].
    MOUTOUSES K; PAPAPANAGIOTOU K; LEKKA D
    Delt Hell Mikrobiol Hygieinol Hetair; 1957; 2(1):3-13. PubMed ID: 13434832
    [No Abstract]   [Full Text] [Related]  

  • 10. The recall phenomenon in the antibody response to influenza vaccines.
    CULVER JO; LENNETTE EH; NAVARRE G; DONAHUE GA
    J Immunol; 1958 Dec; 81(6):452-9. PubMed ID: 13611250
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription.
    Mukhtar MM; Li S; Li W; Wan T; Mu Y; Wei W; Kang L; Rasool ST; Xiao Y; Zhu Y; Wu J
    Int J Biochem Cell Biol; 2009 Mar; 41(3):554-60. PubMed ID: 18687409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Observations on dynamics of influenza antibody formation in the normal population. I. Investigations in collectives of the closed type].
    PROSKURIAKOVA NB
    Mikrobiol Zh; 1955; 17(2):37-40. PubMed ID: 13430394
    [No Abstract]   [Full Text] [Related]  

  • 13. A humanized anti-M2 scFv shows protective in vitro activity against influenza.
    Gabbard J; Velappan N; Di Niro R; Schmidt J; Jones CA; Tompkins SM; Bradbury AR
    Protein Eng Des Sel; 2009 Mar; 22(3):189-98. PubMed ID: 19054791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A commercial ELISA detects high levels of human H5 antibody but cross-reacts with influenza A antibodies.
    Stelzer-Braid S; Wong B; Robertson P; Lynch GW; Laurie K; Shaw R; Barr I; Selleck PW; Baleriola C; Escott R; Katsoulotos G; Rawlinson WD
    J Clin Virol; 2008 Oct; 43(2):241-3. PubMed ID: 18675584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?
    Skowronski DM; Tweed SA; De Serres G
    J Infect Dis; 2008 Feb; 197(4):490-502. PubMed ID: 18275271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretion of bioactive interleukin-6 and tumor necrosis factor-alpha proteins from primary cultured human fetal membrane chorion cells infected with influenza virus.
    Uchide N; Suzuki A; Ohyama K; Bessho T; Toyoda H
    Placenta; 2006; 27(6-7):678-90. PubMed ID: 16122792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the relationship between mean antibody level, seroprotection and clinical protection from influenza.
    Nauta JJ; Beyer WE; Osterhaus AD
    Biologicals; 2009 Aug; 37(4):216-21. PubMed ID: 19268607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-based protein vaccines for influenza.
    Cox MM
    Curr Opin Mol Ther; 2005 Feb; 7(1):24-9. PubMed ID: 15732526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies of local antibody and cellular immune responses to influenza infection and vaccination with live attenuated reassortant influenza vaccine (LAIV) utilizing a mouse nasal-associated lymphoid tissue (NALT) separation method.
    Petukhova G; Naikhin A; Chirkova T; Donina S; Korenkov D; Rudenko L
    Vaccine; 2009 Apr; 27(19):2580-7. PubMed ID: 19428864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 May; 58(19):521-4. PubMed ID: 19478718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.